408 related articles for article (PubMed ID: 33588926)
1. Genetic and environmental determinants of O
Wang L; Mohammadnejad A; Li W; Lund J; Li S; Clemmensen S; Timofeeva M; Soerensen M; Mengel-From J; Christensen K; Hjelmborg J; Tan Q
Clin Epigenetics; 2021 Feb; 13(1):35. PubMed ID: 33588926
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide.
McAleenan A; Kelly C; Spiga F; Kernohan A; Cheng HY; Dawson S; Schmidt L; Robinson T; Brandner S; Faulkner CL; Wragg C; Jefferies S; Howell A; Vale L; Higgins JPT; Kurian KM
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013316. PubMed ID: 33710615
[TBL] [Abstract][Full Text] [Related]
3. Identifying genetic variants regulating MGMT gene expression - A study in monozygotic Danish twins.
Mohammadnejad A; Soerensen M; Mengel-From J; Nygaard M; Timofeeva M; He L; Clemmensen SB; Halekoh U; Dahlrot RH; Tan Q; Hjelmborg JVB
Genomics; 2023 May; 115(3):110616. PubMed ID: 36948276
[TBL] [Abstract][Full Text] [Related]
4. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents.
Siller S; Lauseker M; Karschnia P; Niyazi M; Eigenbrod S; Giese A; Tonn JC
Acta Neuropathol Commun; 2021 Mar; 9(1):35. PubMed ID: 33663593
[TBL] [Abstract][Full Text] [Related]
5. Assessment of MGMT methylation status using high-performance liquid chromatography in newly diagnosed glioblastoma.
Hanihara M; Miyake K; Watanabe A; Yamada Y; Oishi N; Kawataki T; Inukai T; Kondo T; Kinouchi H
Clin Epigenetics; 2020 Nov; 12(1):174. PubMed ID: 33203454
[TBL] [Abstract][Full Text] [Related]
6. A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts.
Malley DS; Hamoudi RA; Kocialkowski S; Pearson DM; Collins VP; Ichimura K
Acta Neuropathol; 2011 May; 121(5):651-61. PubMed ID: 21287394
[TBL] [Abstract][Full Text] [Related]
7. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status.
Bady P; Sciuscio D; Diserens AC; Bloch J; van den Bent MJ; Marosi C; Dietrich PY; Weller M; Mariani L; Heppner FL; Mcdonald DR; Lacombe D; Stupp R; Delorenzi M; Hegi ME
Acta Neuropathol; 2012 Oct; 124(4):547-60. PubMed ID: 22810491
[TBL] [Abstract][Full Text] [Related]
8. Dual MGMT inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma.
Richard S; Tachon G; Milin S; Wager M; Karayan-Tapon L
Cancer Med; 2020 Sep; 9(17):6344-6353. PubMed ID: 32666673
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model.
Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN
J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762
[TBL] [Abstract][Full Text] [Related]
10. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide DNA methylation analysis identifies potent CpG signature for temzolomide response in non-G-CIMP glioblastomas with unmethylated MGMT promoter: MGMT-dependent roles of GPR81.
Liang BB; Wang YH; Huang JJ; Lin S; Mao GC; Zhou ZJ; Yan WJ; Shan CY; Wu HZ; Etcheverry A; He YL; Liu FF; Kang HF; Yin AA; Zhang SQ
CNS Neurosci Ther; 2024 Apr; 30(4):e14465. PubMed ID: 37830163
[TBL] [Abstract][Full Text] [Related]
12. Alteration in the expression of MGMT and RUNX3 due to non-CpG promoter methylation and their correlation with different risk factors in esophageal cancer patients.
Saikia S; Rehman AU; Barooah P; Sarmah P; Bhattacharyya M; Deka M; Deka M; Goswami B; Husain SA; Medhi S
Tumour Biol; 2017 May; 39(5):1010428317701630. PubMed ID: 28468586
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM.
Shah N; Lin B; Sibenaller Z; Ryken T; Lee H; Yoon JG; Rostad S; Foltz G
PLoS One; 2011 Jan; 6(1):e16146. PubMed ID: 21249131
[TBL] [Abstract][Full Text] [Related]
14. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas.
Everhard S; Tost J; El Abdalaoui H; Crinière E; Busato F; Marie Y; Gut IG; Sanson M; Mokhtari K; Laigle-Donadey F; Hoang-Xuan K; Delattre JY; Thillet J
Neuro Oncol; 2009 Aug; 11(4):348-56. PubMed ID: 19224763
[TBL] [Abstract][Full Text] [Related]
15. MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review.
Brandner S; McAleenan A; Kelly C; Spiga F; Cheng HY; Dawson S; Schmidt L; Faulkner CL; Wragg C; Jefferies S; Higgins JPT; Kurian KM
Neuro Oncol; 2021 Sep; 23(9):1457-1469. PubMed ID: 34467991
[TBL] [Abstract][Full Text] [Related]
16. Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients.
Rosas-Alonso R; Colmenarejo-Fernandez J; Pernia O; Rodriguez-Antolín C; Esteban I; Ghanem I; Sanchez-Cabrero D; Losantos-Garcia I; Palacios-Zambrano S; Moreno-Bueno G; de Castro J; Martinez-Marin V; Ibanez-de-Caceres I
Clin Epigenetics; 2021 Mar; 13(1):52. PubMed ID: 33750464
[TBL] [Abstract][Full Text] [Related]
17. Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.
Chai RC; Zhang KN; Liu YQ; Wu F; Zhao Z; Wang KY; Jiang T; Wang YZ
CNS Neurosci Ther; 2019 Mar; 25(3):314-322. PubMed ID: 30117294
[TBL] [Abstract][Full Text] [Related]
18. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.
Amatu A; Sartore-Bianchi A; Moutinho C; Belotti A; Bencardino K; Chirico G; Cassingena A; Rusconi F; Esposito A; Nichelatti M; Esteller M; Siena S
Clin Cancer Res; 2013 Apr; 19(8):2265-72. PubMed ID: 23422094
[TBL] [Abstract][Full Text] [Related]
19. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
[TBL] [Abstract][Full Text] [Related]
20. Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.
Kanemoto M; Shirahata M; Nakauma A; Nakanishi K; Taniguchi K; Kukita Y; Arakawa Y; Miyamoto S; Kato K
BMC Cancer; 2014 Aug; 14():641. PubMed ID: 25175833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]